PReS-FINAL-2161: Safety and effectiveness of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to =4 years weighing <15 kg

Daniel J. Kingsbury,Pierre Quartier,V. Arora,Jasmina Kalabic,Hartmut Kupper,Neelufar Mozaffarian

PReS-FINAL-2161: Safety and effectiveness of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to =4 years weighing <15 kg

2013

Daniel J. Kingsbury
Pierre Quartier
V. Arora
Jasmina Kalabic
Hartmut Kupper
Neelufar Mozaffarian

Adalimumab (ADA) is approved for use in moderate to severe juvenile idiopathic arthritis (JIA) in patients (pts) ≥4 years (yrs) old in the US, EU, and Japan. Limited data are available in pts <4 yrs old.

Keywords:

Passive motion
Arthritis
Rheumatology
Tender joint count
Adalimumab
Juvenile
Pediatrics
Medicine
Internal medicine
moderate to severe
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations